The developments of SGLT2 inhibitors, non-steroidal mineralocorticoid agents, and glucagon-like peptide-1 agonists represent exciting advances in therapeutic options for patients with CKD and possible CRS. Here, SLC5A2 is linked to chronic kidney disease.